MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

KalVista Pharmaceuticals Inc

Abierto

SectorSanidad

13.04 3.49

Resumen

Variación precio

24h

Actual

Mínimo

12.47

Máximo

13.1

Métricas clave

By Trading Economics

Ingresos

-6.2M

-49M

BPA

-0.92

Margen de beneficios

-3,702.322

Empleados

150

EBITDA

4.4M

-41M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+112.58% upside

Dividendos

By Dow Jones

Próximas Ganancias

10 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

4.6M

597M

Apertura anterior

9.55

Cierre anterior

13.04

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

KalVista Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 nov 2024, 21:11 UTC

Principales Movimientos del Mercado

KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering

Comparación entre iguales

Cambio de precio

KalVista Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

112.58% repunte

Estimación a 12 Meses

Media 27.38 USD  112.58%

Máximo 39 USD

Mínimo 19 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para KalVista Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

10

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

11.76 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.